Semaglutide-related weight loss can come with bone loss. Losing weight through diet, surgery, or medication can lower bone mineral density, the amount of mineral in bone. Whether GLP-1 medicines add to that loss, reduce it, or change fracture risk remains unsettled. GLP-1 is a gut hormone involved in appetite and blood sugar.
So, does semaglutide cause bone loss? One small trial found lower spine and hip density. That deserves attention, especially with already fragile bones. It does not mean everyone taking semaglutide develops osteoporosis, a condition that makes bones break more easily.
Does semaglutide cause bone loss in studies?
The clearest direct evidence comes from a Danish trial of 64 adults already at increased fracture risk. Most were women past menopause. Researchers assigned participants by chance to semaglutide or placebo, an inactive comparison treatment, for 52 weeks.
In Hansen and colleagues' trial, published in eClinicalMedicine in 2024, spine and hip density were lower with semaglutide. A blood marker of bone breakdown also rose. The study's main measure, a blood marker of bone formation, did not differ clearly from placebo.
Weight also fell more with semaglutide. Because the comparison group did not lose similar weight, the trial cannot separate weight-related bone loss from a direct drug effect. It was not designed to establish fracture risk.
A later analysis of a 20-person pilot trial in older adults, by Dinkla and colleagues, Frontiers in Aging, 2025, found no statistically clear difference in whole-body density over 20 weeks. Weight loss was small, about 5%, and the authors noted that density was consistently lower at follow-up in the semaglutide group.
As of October 29, 2026, the day this article was written, an October 19 correction fixes reversed group names in its table of starting measurements. The pilot remains too small and short to rule out longer-term loss or changes specifically at the hip and spine.
What the October 2026 bone reviews add
As of October 29, 2026, the day this article was written, a review published October 23 in Archives of Osteoporosis highlights how limited the evidence remains. Lai and colleagues gathered eight randomized trials involving 493 adults with overweight or obesity. They reported four medicines separately rather than combining unlike studies into one result. Evidence certainty was very low for each medicine; semaglutide had just one included trial. The authors also pointed out that the two trials with the most weight loss, one of semaglutide and one of a higher-dose liraglutide, both reported lower spine and hip density, and called for larger trials that track fractures.
As of October 29, 2026, the day this article was written, a broader review by Beaudart and colleagues, published September 12 in Drugs, covered 60 studies: 46 randomized trials, 13 real-world observational studies, and one safety-report study. Its combined analysis of any fracture included 10 studies. The odds ratio, a comparison where 1 means equal odds, was 0.93. Its 95% confidence interval, an uncertainty range, was 0.71–1.22.
That range includes both lower and higher fracture odds. The broader review found no clear overall change in bone density or fractures, but mixed medicines and populations cannot settle one person's semaglutide risk. A lower scan measurement and a broken bone are related outcomes, not interchangeable ones.
What Wegovy, Ozempic, and Zepbound labels say
As of October 29, 2026, the day this article was written, the Wegovy prescribing information marked “Revised: 06/2026” includes a section titled “Fractures.” In SELECT, its heart-outcomes trial, hip and pelvis fractures were reported in:
| Group in that trial | Wegovy | Placebo |
|---|---|---|
| Women | 1% | 0.2% |
| Adults 75 and older | 2.4% | 0.6% |
Those findings came from adults with existing heart or blood-vessel disease. They are not a fracture forecast for everyone taking semaglutide. The label also reports more fractures in a separate trial involving liver inflammation and scarring.
The Ozempic label, revised May 2026, and Zepbound label, revised August 2026, do not list adult bone-density loss or fractures as adverse reactions. None of these labels supplies a bone-density monitoring schedule. A label that says nothing about bone is not proof that there is no risk.
Who gets closer attention to bone health?
Age, low body weight, menopause, and fracture history all matter. The semaglutide and menopause guide covers the wider hormone-related questions.
As of October 29, 2026, the day this article was written, the current USPSTF osteoporosis screening recommendation is dated January 14, 2025. This U.S. preventive-care panel recommends screening women 65 and older, plus younger women past menopause whose risk assessment shows increased risk. Low body weight is one factor it considers.
The recommendation applies to people without known osteoporosis or previous fragility fractures, meaning breaks after minor injury. Someone with either needs an individual clinical assessment. Evidence remains insufficient for a general screening recommendation in men.
Starting semaglutide alone does not create a universal scanning rule. A clinician weighs existing risks and whether testing would change care.
What exercise and nutrition evidence supports
A 2024 JAMA Network Open analysis by Jensen and colleagues studied 195 adults with obesity after an eight-week low-calorie diet. Participants then received exercise, liraglutide, both, or placebo for a year. Liraglutide is another GLP-1 medicine.
Compared with placebo, the combination group preserved hip and spine density despite greater weight loss. Liraglutide alone reduced density at those sites compared with placebo or exercise alone. These were exploratory bone results, and the study does not prove exercise prevents fractures with semaglutide.
The 2025 joint nutrition advisory in the American Journal of Clinical Nutrition emphasizes adequate protein and structured strength exercise. It also supports individualized assessment of vitamin D and calcium needs, with supplements considered when appropriate. It does not establish a supplement combination that prevents semaglutide-related bone loss.
Muscle and bone need attention together. The semaglutide muscle-loss evidence explains why scan changes are not direct muscle measurements. The tirzepatide and exercise guide covers resistance training, activity that challenges muscles against weight.
Is tirzepatide safer for bone density?
That comparison remains unanswered. The published SURMOUNT-1 scan report, Diabetes, Obesity and Metabolism, 2025, reports fat and lean tissue changes, not hip or spine density results. Lean tissue excludes bone mineral. A STEP 1 body-composition conference abstract likewise does not supply those bone-density outcomes.
As of October 29, 2026, the day this article was written, an August 5 observational study in Diabetes/Metabolism Research and Reviews offers another limited clue. Whole-body density stayed stable over a year in 70 adults with obesity and type 1 diabetes, a condition requiring insulin treatment. Only 13 received semaglutide and eight tirzepatide; most received liraglutide. There was no untreated comparison group, and whole-body results cannot establish hip or spine safety.
The separate tirzepatide evidence for older adults adds context, but does not establish that switching medicines protects bones.
How this fits a prescription decision
Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means a pharmacy prepares medication for a prescription. FDA explains that these preparations do not undergo its review for safety, effectiveness, or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor. The cited studies do not establish outcomes for Promise's specific preparation.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The useful discussion includes fracture history, food intake, strength, falls, and the reason for treatment. Bone health belongs in that discussion from the start.
